Why the study?
Does oral acetylsalicylic acid, nebivolol, and atorvastatin therapy improve symptoms in a patient with ST elevation myocardial infarction caused by coronary slow flow?
Does oral acetylsalicylic acid, nebivolol, and atorvastatin therapy improve symptoms in a patient with ST elevation myocardial infarction caused by coronary slow flow?
Answers are grounded in this paper and cite their sources.
Coronary slow flow phenomenon can manifest as ST elevation myocardial infarction and may be successfully managed with acetylsalicylic acid, nebivolol, and atorvastatin.
Coronary Slow Flow Phenomenon (CSFP) is an angiographic phenomenon in which vessel opacification is delayed without any evidence of obstructive epicardial coronary disease. We aim to present, in this paper, extremely slow coronary flow along with its severe clinical manifestation. A 47-year-old male patient was admitted to our emergency department with ST elevation myocardial infarction caused by coronary slow flow. Oral Acetylsalicylic acid, nebivolol and atorvastatin therapy successfully resulted in complete resolution of his symptoms during the 18-month observation.
No takes yet. Share an insight, caveat, or question.
Doğan et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: